Advocating for rituximab as first-line treatment for NMOSD-AQP4 patients in France: Cost and efficacy considerations - 11/10/24
Doi : 10.1016/j.neurol.2024.06.003
Romain Deschamps a, ⁎ 
, Caroline Papeix a, Xavier Ayrignac b, Bertrand Bourre c, Jonathan Ciron d, Mikael Cohen e, Nicolas Collongues f, Kumaran Deiva g, Françoise Durand Dubief h, David-Axel Laplaud i, Elisabeth Maillart j, Laure Michel k, Julie Pique h, Aurélie Ruet l, Eric Thouvenot m, Hélène Zéphir n, Romain Marignier h, Bertrand Audoin o
, Caroline Papeix a, Xavier Ayrignac b, Bertrand Bourre c, Jonathan Ciron d, Mikael Cohen e, Nicolas Collongues f, Kumaran Deiva g, Françoise Durand Dubief h, David-Axel Laplaud i, Elisabeth Maillart j, Laure Michel k, Julie Pique h, Aurélie Ruet l, Eric Thouvenot m, Hélène Zéphir n, Romain Marignier h, Bertrand Audoin o a Department of Neurology, hôpital Fondation Adolphe-de-Rothschild, Paris, France
b Department of Neurology, University Hospital of Montpellier, Montpellier, France
c Department of Neurology, University Hospital of Rouen, Rouen, France
d Department of Neurology, University Hospital of Toulouse, Toulouse, France
e CRC-SEP neurologie Pasteur 2, CHU de Nice, université Cote d’Azur, UMR2CA (URRIS), Nice, France
f Department of Neurology and Department of Pharmacology, Addictology, Toxicology and Therapeutics, Center for Clinical Investigation, Inserm U1434, Biopathology of Myelin, Neuroprotection and Therapeutic Strategy, Inserm U1119, Strasbourg University, Strasbourg, France
g Department of Pediatric Neurology, Bicêtre Hospital, Assistance publique–Hôpitaux de Paris, University Hospitals Paris-Saclay, Le Kremlin-Bicêtre, France
h Service de neurologie, sclérose en plaques, pathologies de la myéline et neuro-inflammation, centre de référence des maladies inflammatoires rares du cerveau et de la moelle (MIRCEM), hôpital neurologique Pierre-Wertheimer, Lyon University Hospital, Lyon, France
i Department of Neurology, CR2TI-Inserm U1064, CIC1314, CHU de Nantes, Nantes université, Nantes, France
j Department of Neurology, centre de référence des maladies inflammatoires rares du cerveau et de la moelle (MIRCEM), hôpital Pitié-Salpêtrière, AP–HP, Paris, France
k Department of Neurology, Inserm UMR 1236, CHU de Rennes, université de Rennes 1, Rennes, France
l Department of Neurology, University Hospital of Bordeaux, Bordeaux, France
m Department of Neurology, University Hospital of Nîmes, Nîmes, France
n Department of Neurology, U 1172, CRC-SEP, University Hospital of Lille, Lille, France
o Department of Neurology, pôle de neurosciences cliniques, hôpital de la Timone, Marseille, AP–HM, Aix Marseille University, Marseille, France
⁎Corresponding author: Department of Neurology, hôpital Fondation Adolphe-de-Rothschild, 25–29, rue Manin, 75940 Paris cedex 19, France.Department of Neurology, hôpital Fondation Adolphe-de-Rothschild25–29, rue ManinParis cedex 1975940France
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.
Conéctese para beneficiarse!
El texto completo de este artículo está disponible en PDF.
Esquema
© 2024
Elsevier Masson SAS. Reservados todos los derechos.
Vol 180 - N° 8
P. 711-714 - octobre 2024 Regresar al número
Artículo precedente
- Contents
- The effectiveness and safety of non-pharmacological intervention for pain management in Parkinson's disease: A systematic review
- M. Huissoud, M. Boussac, K. Joineau, E. Harroch, C. Brefel-Courbon, E. Descamps
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.